Menopause Showdown: EstroG-100 Goes Head-to-Head with Black Cohosh

January 12, 2015

An upcoming study strives to compare an established menopause supplement with a relative newcomer to the market.

After five years on the market, EstroG-100 will be taking on black cohosh in a side-by-side comparison of the most effective option for managing menopause symptoms. Although black cohosh remains the dominant market force in the United States, EstroG-100’s supplier claims its product is the safer, faster-acting alternative to black cohosh.

Michael Jeffers, president of EstroG-100 supplier Helios Corp. (Santa Fe, NM), hopes the study will “define and distance [EstroG] from black cohosh” in the menopause market. The side-by-side study comes in the wake of a third human clinical trial of EstroG completed in August which echoed positive findings of the two prior studies.

“We feel the best way to demonstrate that there is a better and safer choice than black cohosh is to launch a side-by-side study with EstroG-100,” said Jeffers in a press release.

Black cohosh has widespread popularity in the United States for easing menopause symptoms, but Jeffers says it has been dogged in recent years by claims of adulteration, vaginal bleeding, and liver toxicity, including a cautionary directive by the executive director of the North American Menopause Society.

According to Jeffers, EstroG-100 sidesteps such adverse side effects in addition to going into effect faster than black cohosh. In studies, EstroG-100 began working in 7-14 days.

The side-by-side trial will likely take place in the United States and feature 60 participants. Jeffers expects the study to last 2-3 months.

EstroG-100 is backed by New Dietary Ingredient (NDI) status from FDA and is non-estrogenic. The herbal product combines Angelica gigas root extract, Cynanchum wilfordii root extract, and Phlomis umbrosa root extract. Three human studies have shown success lessening hot flashes, vaginal dryness, sleeplessness, fatigue, dizziness, nervousness, and menopause-related blues without adverse effects.

Jeffers reports EstroG-100 has 85% of the entire menopause market in South Korea, but only a small slice of the U.S. market. With positive results of the side-by-side study, he hopes that slice will continue to grow.

 

Michael Crane
Associate Editor
Nutritional Outlook magazine
michael.crane@ubm.com

 

Photo © iStockphoto.com/asiseeit